| Q61886048 | A History of the Pharmacological Treatment of Bipolar Disorder |
| Q51530550 | A computerised sampling strategy for therapeutic drug monitoring of lithium provides precise estimates and significantly reduces dose-finding time. |
| Q27004676 | A decision analysis of long-term lithium treatment and the risk of renal failure |
| Q33284843 | A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? |
| Q34033368 | Abnormalities in mitochondrial structure in cells from patients with bipolar disorder |
| Q35236966 | Acute and long-term treatment of mania. |
| Q37725149 | Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). |
| Q34401213 | An update on antiepileptic drugs and suicide: are there definitive answers yet? |
| Q36624146 | Antidepressants and suicidal behavior in bipolar disorder |
| Q56891225 | Antiepileptic drugs and suicide-related outcomes in bipolar disorder: A descriptive review of published data |
| Q36813488 | Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study |
| Q82640944 | Are antidepressants warranted in the treatment of patients who present suicidal behavior? |
| Q37356508 | Assessment and treatment of suicide risk in bipolar disorders |
| Q81663512 | Association of 14-3-3 epsilon gene haplotype with completed suicide in Japanese |
| Q36286401 | Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression |
| Q57479304 | Bipolar Disorder Mixed Episodes: A Pragmatic Trial of a Public Health Treatment Effectiveness |
| Q92426910 | Bipolar depression: a major unsolved challenge |
| Q36681303 | Bipolar depression: a review of randomised clinical trials |
| Q37952587 | Bipolar depression: an evidence-based approach |
| Q36634433 | Bipolar depression: diagnostic and treatment considerations |
| Q35236988 | Bipolar depression: trial-based insights to guide patient care. |
| Q34300877 | Can we really prevent suicide? |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q36201085 | Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory |
| Q38556588 | Changing Trends in Treatment of Acute Mania: Experience of a Tertiary Centre Over a Decade |
| Q35831460 | Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder |
| Q38097098 | Clinical assessment and crisis intervention for the suicidal bipolar disorder patient |
| Q57697974 | Clinical factors associated with lithium response in bipolar disorders |
| Q33629354 | Clinical psychologists' firearm risk management perceptions and practices |
| Q92061330 | Clinical use of lithium salts: guide for users and prescribers |
| Q36067140 | Commentary: bipolar disorder is a potentially fatal disease. |
| Q89665749 | Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better |
| Q34575982 | Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD |
| Q51920039 | Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. |
| Q46713324 | Current management of bipolar affective disorder: is it reflective of the BAP guidelines? |
| Q34574031 | Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review |
| Q35688484 | Differential effects of antidepressants escitalopram versus lithium on Gs alpha membrane relocalization |
| Q43115152 | Does lithium save lives? |
| Q38758442 | Drug Interactions with Lithium: An Update |
| Q43431795 | Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. |
| Q83215397 | Easing the burden of bipolar disorder: from urgent situations to remission |
| Q36879689 | Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder |
| Q40462745 | Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core struc |
| Q37664710 | Enhancing medication adherence in patients with bipolar disorder |
| Q34064341 | Enhancing medication adherence: in older adults with bipolar disorder |
| Q38113575 | Epidemiology of suicide in bipolar disorders: a systematic review of the literature |
| Q37424330 | Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder |
| Q36510907 | Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review |
| Q34188388 | Evidence-Based Strategies Improve Assessment of Pediatric Bipolar Disorder by Community Practitioners |
| Q90111514 | Fatal and Non-fatal Self-Injury in the USA: Critical Review of Current Trends and Innovations in Prevention |
| Q45053879 | Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). |
| Q36096851 | Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs |
| Q35847010 | Impact of bipolar disorder: results from a screening study. |
| Q38122748 | Impact of psychotropic drugs on suicide and suicidal behaviors |
| Q39066912 | Improving lithium therapeutics by crystal engineering of novel ionic cocrystals |
| Q36951439 | Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development |
| Q36251776 | Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation |
| Q38839931 | Interventions to prevent self-harm: what does the evidence say? |
| Q37073680 | Issues in co-morbid severe mental illnesses in HIV infected individuals |
| Q38051077 | Juvenile bipolar disorder and suicidality: a review of the last 10 years of literature |
| Q38724561 | LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice. |
| Q47771489 | Lithium and suicide in mood disorders: Updated meta-review of the scientific literature |
| Q38240532 | Lithium for bipolar disorder: a review of the recent literature |
| Q42958110 | Lithium for older adults with bipolar disorder: Should it still be considered a first-line agent? |
| Q28076935 | Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations |
| Q44973814 | Lithium in bipolar and other affective disorders: prescribing practice in the UK. |
| Q37394038 | Lithium in tap water and suicide mortality in Japan |
| Q38211605 | Lithium in the treatment of major depressive disorder |
| Q34642207 | Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity |
| Q42640514 | Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design |
| Q37103372 | Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice |
| Q39238241 | Lithium: A classic drug-Frequently discussed, but, sadly, seldom prescribed! |
| Q36905840 | Lithium: a novel treatment for Alzheimer's disease? |
| Q37423318 | Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder |
| Q38764874 | Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents |
| Q33810132 | Long noncoding RNA expression in peripheral blood mononuclear cells and suicide risk in Chinese patients with major depressive disorder. |
| Q34117647 | Long-term lithium treatment and thyroid antibodies: a controlled study. |
| Q82337323 | Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients |
| Q34343896 | Managing bipolar depression |
| Q34156483 | Misdiagnosis of bipolar disorder |
| Q36119897 | Mood stabilization in the treatment of bipolar disorder: focus on quetiapine |
| Q37343344 | NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER. |
| Q46601299 | Newer prophylactic agents for bipolar disorder and their influence on suicidality |
| Q38632654 | Pharmaceutical cocrystals: along the path to improved medicines |
| Q43228395 | Pharmacological treatment of impulsivity and aggressive behavior |
| Q36649087 | Pharmacotherapy of bipolar depression: an update |
| Q36195190 | Pharmacotherapy of suicidal behavior in bipolar disorder |
| Q41888671 | Plasma and Brain Pharmacokinetics of Previously Unexplored Lithium Salts |
| Q37484098 | Polarity of the first episode and time to diagnosis of bipolar I disorder |
| Q44281926 | Post-discharge suicides of inpatients with bipolar disorder in Finland |
| Q34325612 | Potential mechanisms of action of lithium in bipolar disorder. Current understanding |
| Q36150677 | Prepubertal bipolar disorder: available pharmacological treatment options |
| Q34098311 | Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. |
| Q36243152 | Preventing suicidal behaviour in a general hospital psychiatric service: priorities for programming |
| Q40705907 | Psychopharmacologic Services for Homeless Veterans: Comparing Psychotropic Prescription Fills Among Homeless and Non-Homeless Veterans with Serious Mental Illness |
| Q93014347 | Psychotropic Medication of Acute Episodes of Mood Disorders: Current Prescription Attitude in Two Psychiatric Wards in Cagliari, Italy |
| Q62868812 | Psychotropic effects of antiepileptic drugs |
| Q37589106 | Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder |
| Q46696474 | Renal function in geriatric psychiatry patients compared to non-psychiatric older adults: effects of lithium use and other factors |
| Q45044484 | Risk of suicide attempt and suicide death in patients treated for bipolar disorder |
| Q93558248 | Risk of suicide in bipolar disorder is least with lithium |
| Q36199036 | Safety and tolerability of emerging pharmacological treatments for bipolar disorder |
| Q33606886 | Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns. |
| Q35946071 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders |
| Q57612842 | Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels |
| Q37868003 | Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? |
| Q36565679 | Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study. |
| Q38932319 | Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment |
| Q35690425 | Suicidal ideation in depressed postpartum women: Associations with childhood trauma, sleep disturbance and anxiety |
| Q57612798 | Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment |
| Q40340872 | Suicidality in bipolar I disorder |
| Q46573540 | Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors. Review and meta-analysis of the available randomised, placebo controlled trials |
| Q34494779 | Suicide and suicidal behaviour |
| Q38629803 | Suicide attempts in bipolar disorders: comprehensive review of 101 reports. |
| Q34240226 | Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics |
| Q44085213 | Suicide in a large population of former psychiatric inpatients |
| Q44560054 | Suicide in bipolar I disorder in Finland: psychological autopsy findings from the National Suicide Prevention Project in Finland |
| Q36525750 | Suicide in bipolar disorder: Risks and management. |
| Q38189070 | Suicide prevention as a prerequisite for recovery from severe mental illness |
| Q46615999 | Suicide prevention by lithium SUPLI--challenges of a multi-center prospective study |
| Q34530580 | Suicide prevention strategies revisited: 10-year systematic review |
| Q36309012 | Suicide prevention: a pragmatic review of recent studies |
| Q35129198 | Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study |
| Q36836763 | Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? |
| Q84984712 | Suicide-Related Events in Patients Treated with Antiepileptic Drugs |
| Q34182827 | Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q33664736 | The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders |
| Q34550618 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q37954431 | The effect of pharmacotherapy on suicide rates in bipolar patients. |
| Q37999012 | The effects of lithium on renal function in older adults--a systematic review |
| Q36195205 | The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. |
| Q34445375 | The molecular bases of the suicidal brain |
| Q35099048 | The neuroscience of suicidal behaviors: what can we expect from endophenotype strategies? |
| Q37321565 | The presentation, recognition and management of bipolar depression in primary care |
| Q24651407 | The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis |
| Q37990676 | The science and practice of lithium therapy |
| Q35858926 | The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review |
| Q47873112 | The surprising blindness in modern psychiatry: do guidelines really guide? |
| Q41431544 | The treatment of bipolar patients with elevated impulsivity and suicide risk. |
| Q36106769 | Treatment of bipolar depression: focus on pharmacologic therapies |
| Q37158292 | Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior |
| Q42606458 | Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. |
| Q38760853 | Use of Prescription Medication by Individuals Who Died by Suicide in Northern Ireland |
| Q40734362 | Use of lithium and the risk of injurious motor vehicle crash in elderly adults: case-control study nested within a cohort. |
| Q46706734 | Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells |
| Q35022930 | Women and bipolar disorder across the life span |
| Q50169597 | Working, receiving disability benefits, and access to mental health care in individuals with bipolar disorder |
| Q34578945 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care |
| Q83107883 | [Mixed states in bipolar disorders: a review of current therapeutic strategies] |